Activity of epirubicin in combination chemotherapy of advanced ovarian cancer. Results of the South-East European Oncology Group (SEEOG) Study

Autor:	S, Eckhardt, J, Szántó, O, Cerar, V, Chylak, Z, Hernádi, I, Hindy, S, József, E, Juhos, K, Kolaric, J, Kopecny
Rok vydání:	1987
Předmět:	Adult Ovarian Neoplasms Clinical Trials as Topic Remission Induction Stereoisomerism Middle Aged Doxorubicin Humans Drug Therapy Combination Female Cisplatin Cyclophosphamide Aged Epirubicin
Zdroj:	Oncology. 44(2)
ISSN:	0030-2414
Popis:	The therapeutic efficacy of the combination of cyclophosphamide + epirubicin + cisplatin was evaluated in 107 previously treated or untreated patients with advanced ovarian cancer. The overall response rate was 58.8%, complete remission 36.4% (mean duration-7.62 months) and partial remission 22.4% (mean duration-6.74 months). The response was rated in function of age, menopausal status, performance status and previous therapy. Toxicity (in case of 109 patients) was evaluated according to the WHO recommendation. The similar therapeutic effectiveness and less toxicity of the above drug combination compared to CAP regimen is demonstrated.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::7a6ebfb21cedb40aeafb4837a68ea016 https://pubmed.ncbi.nlm.nih.gov/3554083 Zobrazit plný text záznamu